Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 4
Abstract
A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected. The creatine kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline. The patient’s renal function remained unaffected. Fourteen days after hospitalization, creatine kinase level had returned to 230 IU/L and the patient was discharged. Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale. The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance. Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood. In conclusion, with this case we illustrate that telaprevir as well as statins are susceptible to clinical relevant drug-drug interactions.
Authors and Affiliations
Clara TMM de Kanter, Caroline Solas, Matthijs van Luin, David M Burger, Jan Maarten Vrolijk
Keywords
Related Articles
- EP ID EP78424
- DOI -
- Views 139
- Downloads 0
A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma
Background and rationale for the study. Continuing search for suitable tumor-markers is of clinical value in managing patients with various malignancies. These markers may be presented as intracellular substances in tiss...
Raloxifene hydrochloride as hepatitis C treatment
Association of HLA-DQ and IFNL4 polymorphisms with susceptibility to hepatitis B virus infection and clearance
Background and aim. Leukocyte antigen DQ (HLA-DQ) and interferon-λ4 (IFNL4) gene polymorphisms were associated withsusceptibility to chronic hepatitis B and C virus infection. This study further confirmed that variants...
Reply to the letter to the Editor
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial
Introduction. The burden of non-alcoholic steatohepatitis (NASH) is growing and current pharmacologic treatments are limited by side effects and inconsistent efficacy. Pilot studies suggest that pentoxifylline (PTX) can...